Comparison · NCT01864603-6c3c8182
Intervention vs Control: Prevalence of Transmitted HIV Drug-resistance Mutations
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Intervention vs Control: Prevalence of Transmitted HIV Drug-resistance Mutations. Trial comparisons, record NCT01864603-6c3c8182. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01864603-6c3c8182
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.108 | 0.0558 | 0.199 | wilson | |
| Risk in group 2 | 0.103 | 0.0584 | 0.175 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0053 | -0.0837 | 0.107 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.05 | 0.444 | 2.49 | log | |
| Odds ratio, group 1 over group 2 | 1.06 | 0.404 | 2.77 | log | |
| Number needed to treat, for one more participant with the outcome on Intervention than on Control | 189 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Intervention | Baseline universal community-based HIV and multi-disease testing; ART eligibility for all HIV+; ART delivery using streamlined patient-centered care; targeted population-level PrEP | 8 | 74 | OG000 |
| Group 2 | Control | Baseline community-based HIV and multi-disease testing; ART eligibility and delivery by country standard of care | 11 | 107 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Prevalence of Transmitted HIV Drug-resistance Mutations
- Description
- HIV NNRTI drug-resistance mutations found at baseline
- Time frame
- Baseline
- Population
- ART naive HIV+ persons at baseline
Source ClinicalTrials.gov
Trial
- Title
- Sustainable East Africa Research in Community Health
- NCT number
- NCT01864603
- Phases
- NA
- Conditions
- HIV, Tuberculosis, Hypertension, Diabetes, Maternal Child Health, Cost Effectiveness
- Interventions
- Universal ART in a streamlined care model, Annual Community Health Campaigns, Targeted PrEP and Targeted testing interventions, Baseline community-based HIV and multi-disease testing
- Lead sponsor
- University of California, San Francisco
- Results first posted
- 2022-03-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01864603?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01864603-6c3c8182